Analysts’ Opinions Are Mixed on These Healthcare Stocks: Seattle Genetics (NASDAQ: SGEN), Myriad Genetics (NASDAQ: MYGN) and Coherus Biosciences (NASDAQ: CHRS)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Seattle Genetics (NASDAQ: SGEN), Myriad Genetics (NASDAQ: MYGN) and Coherus Biosciences (NASDAQ: CHRS).

Seattle Genetics (NASDAQ: SGEN)

In a report issued on June 19, Geoff Meacham from Barclays maintained a Hold rating on Seattle Genetics (NASDAQ: SGEN), with a price target of $55. The company’s shares closed yesterday at $63.25.

According to TipRanks.com, Meacham is a 4-star analyst with an average return of 10.1% and a 58.7% success rate. Meacham covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, DBV Technologies SA – American, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Seattle Genetics is Moderate Buy and the average price target is $58.38, representing a -7.7% downside.

In a report issued on June 19, Piper Jaffray also maintained a Hold rating on the stock with a $48 price target.
Myriad Genetics (NASDAQ: MYGN)

Barclays analyst Jack Meehan maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN) on June 21 and set a price target of $28. The company’s shares closed yesterday at $26.26.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.2% and a 73.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Thermo Fisher, and PerkinElmer.

Currently, the analyst consensus on Myriad Genetics is Moderate Sell and the average price target is $21.33, representing a -18.8% downside.

In a report issued on June 12, Jefferies also reiterated a Hold rating on the stock with a $21 price target.
Coherus Biosciences (NASDAQ: CHRS)

In a report issued on June 21, Douglas Tsao from Barclays maintained a Buy rating on Coherus Biosciences (NASDAQ: CHRS), with a price target of $30. The company’s shares closed yesterday at $15.80, close to its 52-week low of $14.

According to TipRanks.com, Tsao is a 3-star analyst with an average return of 4.7% and a 54.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, CoLucid Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Coherus Biosciences is Strong Buy and the average price target is $36.50, representing a 131.0% upside.

In a report issued on June 12, Credit Suisse also maintained a Buy rating on the stock with a $24 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.